Next-generation of selective histone deacetylase inhibitors

被引：94

作者：

Yang, Feifei ^{[1
,2
,3
]}

Zhao, Na ^{[1
]}

Ge, Di ^{[1
]}

Chen, Yihua ^{[2
,3
]}

机构：

[1] Univ Jinan, Sch Biol Sci & Technol, Jinan 250022, Shandong, Peoples R China

[2] East China Normal Univ, Shanghai Key Lab Regulatory Biol, Inst Biomed Sci, Shanghai 200241, Peoples R China

[3] East China Normal Univ, Sch Life Sci, Shanghai 200241, Peoples R China

来源：

RSC ADVANCES | 2019年 / 9卷 / 34期

基金：

中国国家自然科学基金;

关键词：

DIVERSITY-ORIENTED SYNTHESIS; BIOLOGICAL EVALUATION; HDAC INHIBITORS; CANCER-THERAPY; MOLECULAR-MECHANISMS; ISOFORM SELECTIVITY; EPIGENETIC THERAPY; ACID-DERIVATIVES; RATIONAL DESIGN; ACTIVITY ASSAY;

D O I：

10.1039/c9ra02985k

中图分类号：

O6 [化学];

学科分类号：

0703 ;

摘要：

Histone deacetylases (HDACs) are clinically validated epigenetic drug targets for cancer treatment. HDACs inhibitors (HDACis) have been successfully applied against a series of cancers. First-generation inhibitors are mainly pan-HDACis that target multiple isoforms which might lead to serious side effects. At present, the next-generation HDACis are mainly focused on being class- or isoform-selective which can provide improved risk-benefit profiles compared to non-selective inhibitors. Because of the rapid development in next-generation HDACis, it is necessary to have an updated and state-of-the-art overview. Here, we summarize the strategies and achievements of the selective HDACis.

引用

页码：19571 / 19583

页数：13

共 50 条

[31] Histone deacetylase inhibitors
Miller, TA
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2005, 229 : U162 - U162
[32] Histone deacetylase inhibitors
Marks, PA
Richon, VM
Miller, T
Kelly, WK
ADVANCES IN CANCER RESEARCH, VOL 91, 2004, 91 : 137 - +
[33] Optimization of a series of potent and selective ketone histone deacetylase inhibitors
Pescatore, Giovanna
Kinzel, Olaf
Attenni, Barbara
Cecchetti, Ottavia
Fiore, Fabrizio
Fonsi, Massimiliano
Rowley, Michael
Schultz-Fademrecht, Carsten
Serafini, Sergio
Steinkuehler, Christian
Jones, Philip
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2008, 18 (20) : 5528 - 5532
[34] The Process and Strategy for Developing Selective Histone Deacetylase 3 Inhibitors
Cao, Fangyuan
Zwinderman, Martijn R. H.
Dekker, Frank J.
MOLECULES, 2018, 23 (03):
[35] Investigation and synthesis of isoform-selective histone deacetylase inhibitors
O'Neill, Matthew
Wiest, Olaf
Helquist, Paul
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2017, 253
[36] Bioluminescent cell models for the detection of selective histone deacetylase inhibitors
Linares, A.
Boulahtouf, A.
Boulle, N.
Busson, M.
Balaguer, P.
Cavailles, V
BULLETIN DU CANCER, 2008, 95 : S18 - S18
[37] Polyaminohydroxamic acids and polyaminobenzamides as isoform selective histone deacetylase inhibitors
Varghese, Sheeba
Senanayake, Thulani
Murray-Stewart, Tracey
Doering, Kim
Fraser, Alison
Casero, Robert A., Jr.
Woster, Patrick M.
JOURNAL OF MEDICINAL CHEMISTRY, 2008, 51 (08) : 2447 - 2456
[38] A novel series of potent and selective histone deacetylase inhibitors.
Jones, Philip
Altamura, Sergio
Chakravarty, Prasun K.
Ingenito, Raffaele
Petrocchi, Alessia
Rowley, Michael
Scarpelli, Rita
Serafini, Sergio
Steinkuhler, Christian
CANCER RESEARCH, 2006, 66 (08)
[39] Design of selective histone deacetylase inhibitors: rethinking classical pharmacophore
Melesina, Jelena
Praetorius, Lucas
Simoben, Conrad V.
Robaa, Dina
Sippl, Wolfgang
FUTURE MEDICINAL CHEMISTRY, 2018, 10 (13) : 1537 - 1540
[40] Selective Inhibitors of Histone Deacetylase 10 (HDAC-10)
Pojani, Eftiola
Barlocco, Daniela
CURRENT MEDICINAL CHEMISTRY, 2022, 29 (11) : 2306 - 2321

← 1 2 3 4 5 →